Skip to main content

Open Primary Retroperitoneal Lymph Node Dissection Shows Acceptable Morbidity

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 5, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Nov. 5, 2024 -- Open primary retroperitoneal lymph node dissection (RPLND) has an acceptable morbidity profile in men with testicular cancer, according to a study published online Sept. 3 in BJU International.

Jacob D. McFadden, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues characterized current perioperative outcomes and short-term complication rates for open primary retroperitoneal lymph node dissection. The analysis included 165 patients undergoing surgery from 2018 to 2021.

The researchers found that patients most often had clinical stage IIA (39 percent) or IIB testicular cancer (36 percent). No transfusions were required, and median estimated blood loss was 150 mL. Compared with normal recovery, higher body mass index (median, 28.6 kg/m2) was seen in patients who sustained any complication. Three days was the median length of hospital stay. There was a low overall complication rate (8.48 percent), with two major postoperative complications, including one case of chylous ascites (0.6 percent). No deaths were seen in the 30-day period.

"While contemporary reports on the robotic approach to primary RPLND indicate feasibility and potential benefits with respect to blood loss and hospital stay, our report suggests that the open approach remains the ‘gold standard’ by most peri-operative metrics," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

Read this next

Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections

WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...

AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...

AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors

TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.